University of Crete (UOC)
Εκτίμησης μοριακών παραγόντων σε ασθενείς με μεταστατικό καρκίνο του παχέoς εντέρου που έχουν λάβει θεραπεία πρώτης γραμμής και συσχέτισή τους με την ανταπόκριση στην θεραπεία και την επιβίωση
Abstract
dc:descriptionINTRODUCTIONDespite advances in diagnosis and treatment, colorectal cancer (CRC) remains a major publichealth problem. It is estimated that one million new cases are diagnosed worldwide everyyear. The majority of the cases are not associated with any underlying condition whilerecognized risk factors for CRC are male sex, age, bowel polyps and various environmentalfactors.The last decade there has been a marked improvement in the survival of patients with CRC.This is partly due to the improved screening and early diagnosis methods and also due tothe more efficient surgical and pharmacological treatment options. The guaic-based feacaloccult blood test and sigmoidoscopy / colonoscopy are the preferred screening tools. On theother hand efficacy of pharmacological treatments is increased as a result of our betterunderstanding of the molecular mechanisms of cancer that (a) aid in the development ofnovel compounds and (b) help identify groups of patients more likely to benefit fromspecific treatments.The optimal treatment for the newly diagnosed patient with CRC is surgical resection of the primary tumour, whenever this is possible, followed by the administration of systemicchemotherapy. In the recent years a new class of drugs, the targeted therapies (TT), haveshown to be beneficial in patients with CRC. One of the advantages of TT is that they blockvital functions of the cancer cells while affecting little the healthy tissues. Another aspect oftreatment optimization is patient selection. To that end our better understanding ofmolecular biology is pivotal. The recognition of cancer-promoting alterations in the genomeof malignant cells helps not only in the development of targeted therapies but also asprognostic and predictive biomarkers. A specific example is the gene that encodes for theprotein BRAF. BRAF is a protein that participates in the RAS-RAF-MEK-ERK-MAP kinasepathway that mediates cellular responses to growth signals. When the gene encoding forBRAF is mutated, specifically a single substitution missense mutation (V600E), it leads to theproduction of a continuously activated protein that has been shown to have a critical role in the development of malignant tumors such as melanoma. The mutated variant of BRAF(V600E) is detected in 8-10% of patients with CRC as per recent reports, but its role as apredictive or prognostic biomarker is not yet clear.The microsatellite instability of DNA (MSI) is characterized by the absence of proteinexpression encoded by the corresponding mismatch repair (MMR) genes (hMLH1, hMSH2,hMSH6). MSI is observed in the vast majority of patients with hereditary non-polyposiscolon cancer and in 20% of patients with sporadic CRC. In the sporadic form the MMR genesare inactivated due to epigenetic methylation in the promoter region of hMLH1 or byalteration of the hMSH2 or hMSH6 genes. Microsatellite genotyping of CRC patients is basedon specific standard criteria using specific panels. The use of MSI as predictive and/ orprognostic biomarker is not sufficiently clarified.Cyclin D1 is a G protein that with the aid of cyclins D2 and D3 activate the cyclin dependentkinases 4 and 6. Extracellular signals, such as growth factor receptor activation, influencecyclin D transcription and translation resulting in mitogenic signaling within the cell cyclemachinery. The deregulation of cyclin expression can lead to uncontrolled proliferation independent of extracellular stimuli. Cyclin D1 is a well-established oncogene with evidencesuggesting that when amplified or overexpressed can contribute in the development ofbreast cancer. The role of cyclin D1 in CRC is less well understood nevertheless, it isimplicated in EGFR signaling a pathway of special interest in patients with CRC.The aim of the present project is to identify the role of BRAF, MSI and cyclin D1 in themolecular mechanisms that lead to CRC and investigate their role as potential predictive and/ or prognostic biomarkers.METHODA total of 144 consecutive patients, with histologically confirmed CRC and available tumormaterial for molecular analysis, who were treated in the University Hospital of Heraklion,between January 2002 and December 2006 were included in the study. The study had all thenecessary formal approvals and patients gave their informed consent prospectively. Allpatients had documented metastatic disease and received 5-FU based chemotherapy. Formalin-fixed, paraffin embedded tumor sections were reviewed by an experiencedpathologist to confirm the diagnosis and assess the suitability of the samples for furtheranalysis. The V600E BRAF mutation was detected with the use of real-time PCR (RT-PCR)using the allelic discrimination method. For the immunohistochemical staining of the MMRproteins two antibodies were used, specifically anti-hMLH1, anti-hMSH2 and for cyclin D1the anti-cyclin D1 antibody. The immunostaining kit used was the UltraVision large volumedetection system AP Polymer. The dilutions of the antibodies were: (a) hMLH1 1:50, (b)hMSH2 1:50 and (c) cyclin D1 1:25. Positive and negative staining controls were used in allcases. Microsatellite instability was evaluated in all samples using the five reference markersof the NCI panel in addition to two markers suggested from alternative panels. PCR, usingsingle strand conformation polymorphism in a non denaturing environment, was used forthe above mentioned molecular markers. All PCR analyses were repeated twice to confirmthe validity of the results. If >30% of the loci examined showed MSI, the tumor wasclassified as MSI-H whereas if <30% of loci displayed MSI then the tumor was labeled asMSI-L or MSS.Associations between BRAF mutation status, d-MMR, cyclin D1 expression and baselinecharacteristics were assessed using the Fisher’s exact test for categorical variables or logisticregression for continuous variables. PFS was measured from the date of initiation of firstline chemotherapy until the radiologic confirmation of progressive disease or death. Overallsurvival was calculated from date of diagnosis of metastatic CRC until death.RESULTSThe median age of patients was 64 years and 57% of them were men. Metastasectomy wasperformed in 21 (15%) patients. The BRAF V600E mutation and tumors characterized asMSI-H were 12 (8%) and 22 (15%) respectively. Cyclin D1 was overexpressed in 26 (18%)patients while it was weakly expressed in 63 (44%) and not expressed in 55 (38%).The median time from initial diagnosis to the radiological documentation of metastaticdisease was 19.3 months (95% CI 14.6-20.3). Median interval from diagnosis of metastaticCRC to initiation of chemotherapy was 0.8 months (95% CI 0.5-1.1). All patients received 5-FU based treatment. At the time of the analysis 132 out of the 144 (92%) patients weredeceased – 128 due to progressive CRC.BRAF mutations were found with increased frequency in tumors characterized as MSI-H ascompared to MSI-L or MSS tumors (45% and 1.6% respectively, p=0.001). In addition theBRAF mutations were also correlated with cyclin D1 overexpression. Specifically cyclin D1was overexpressed in 58% of BRAF V600E tumors compared to 14% of BRAF wild-typetumors (p=0.001).The median PFS of the patient population enrolled was 9.5 months (95% CI 8.4-10.8) andthe median overall survival was 31.5 months (95% CI 26.4-37.7). Patients with wild typeBRAF had significantly increased survival and PFS compared to patients with BRAF V600E (30vs 14 months and 9.8 vs 2.7 months respectively). Univariate analysis revealed significantassociations of PFS with undifferentiated tumor histology (p=0.001), BRAF mutations(p<0.001) and no metastasectomy (p<0.001). Overall survival was associated with tumordifferentiation (p<0.001), BRAF mutations (p<0.0001), no metastasectomy (p=0.03) andfinally the sum of chemotherapy lines the patient received (p=0.02).In multivariate analysis, BRAF V600E and tumor grade were found to be independentprognostic factors for reduced PFS (HR 2.8, 95% CI 1.4-5.7, p=0.004 and HR 2.0 95% CI 1.3-3.2, p=0.001 respectively) and OS (HR 5.3, 95% CI 2.5-11.3, p<0.001 and HR 2.6, 95% CI 1.6-4.4, p<0.001 respectively).Forty-eight patients (33%) were treated with cetuximab, 13 (31%) of them carrying themutated allele of KRAS in their primary tumors. Interestingly, KRAS and BRAF mutationswere found to be mutually exclusive. The presence of either mutation was significantlycorrelated with decreased PFS (p=0.013) and median overall survival (p=0.003).DISCUSSIONOur results indicate that patients with CRC who tumors harbor the mutated variant of BRAFhave a significantly lower PFS and OS compared to patients with wild-type BRAF. In addition,the mutated BRAF is predictive of poor response to cetuximab, an anti-EGFR antibody. Inour study we report a median OS of 31.5 months which is higher compared to other studies. Some of the reasons are: (a) a significant percentage of patients underwentmetastasectomy following first line chemotherapy. Metastasectomy, has been shown toincrease survival and should be pursued when feasible. (b) the majority of the patients inthe study received all three chemotherapeutic drugs in the course of their treatment andfinally (c) 45% of the patients received cetuximab and bevacizumab.In our study the incidence of BRAF V600E was significantly higher in tumors characterized asMSI-H or tumors that overexpressed cyclin D1. Given that approximately half of the patientswith MSI-H had mutated BRAF, a predictive biomarker for cetuximab, we hypothesize thatpatients with known MSI-H status could possibly benefit from BRAF assessment prior totreatment with anti-EGFR antibodies.In summary, patients that have the mutant BRAF represent a population with poorprognosis. Furthermore, treatment with anti-EGFR antibodies should not be routine inpatients with BRAF mutations. On the other hand, we should note that these results need tobe validated prospectively in randomized trials before applied in clinical practice.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadatos-Pastos, Dionysios
- Παπαδάτος-Πάστος, Διονύσιος
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38066